July 19, 2017 -- China will add 36 new drugs to its list of insurance-covered products after their manufacturers agreed to deep price cuts. China’s Ministry of Human Resources said the cuts averaged 44% and reached a high of 70%. There were 31 western drugs -- 15 of them for cancer -- included in the list of newly added products and five Traditional Chinese Medicines. Big names for cancer in the adds included Roche’s Herceptin, Avastin and MabThera; Celgene’s Revlimid; J&J’s Zytiga and Novartis’ Afinitor.
